ABSTRACT
Oral lichen planus is an autoimmune inflammatory disease. Tumor necrosis factor alpha [TNF-alpha] is an important cytokine with a large number of biological effects which is implicated in the pathogenesis of the disease. The present study was conducted to measure and compare the level of TNF-alpha in sera and saliva of patients with OLP. The study included 30 patients suffering from OLP. They were divided into 2 groups: erosive OLP [15 patients] and reticular OLP [15 patients]. The study also included 10 ages and sex matched healthy subjects as control group. TNF-alpha was measured in sera and saliva by enzyme linked immunosorbent assay method
Results: TNF -alpha in sera of OLP patients was statistically higher than in control group [6.39 +/- 1.82 pg/ml compared to 2.99 +/- 0.52 pg/ml, P < 0.0001]. Also TNF-alpha in sera of erosive OLP was statistically higher than in sera of reticular OLP [7.87 +/- 1.16 Pg/ml compared to 4.90 +/- 0.90 pg/ml, P <0.0001] and TNF-alpha in erosive or reticular OLP was significantly higher than in the control group [P < 0.0001]. Regarding salivary TNF-alpha the study showed that salivary TNF-alpha in OLP patients was statistically higher than in the control group [28.20 +/- 5.00 pg/ml compared to 6.91 +/- 0.98 pg/ml, P < 0.0001]. The study also showed that salivary TNF-alpha was statistically higher in erosive type than in reticular type and each of them was higher than the control group [31.75 +/- 3.75 pg/ml in erosive type, 24.56 +/- 3.15 pg/ml in reticular type and 6.91 +/- 0.98 pg/ml in the control group, P = < 0.0001 in all]. The study also showed that a positive correlation was present between salivary and serum TNF-alpha, and salivary TNF-alpha was always higher than serum TNF-alpha
Conclusion: salivary TNF-alpha is a non-invasive more sensitive technique that can be used to detect disease activity and monitor the therapeutic response in OLP
ABSTRACT
This work aimed to investigate the biochemical changes of serum sFas/sFasL system and its usefulness as an apoptogenic marker in patients with cancer breast, as a trial to approach serum biomarker which may be of value in early diagnosis and screening of patients with cancer breast. Fourty patients non pregnant, non lactating females were categorized into 20 patients with breast cancer [BC], subclassified according to the clinical and mammographic staging and TNM classification into BC1 [13 patients] with T1NOMO lesion, and BC2 [7 patients] with T2NOMO lesion. Twenty patients with benign breast lesions subclassified into [12 patients] with fibroadenoma [FA1] and [8 patients] with fibroadenosis [FA2]. Another, 20 healthy females with matched age, served as control. This study revealed a significant increase in the preoperative serum sFas/CD95 and sFasL in BC1 and BC2 compared to both control and benign breast lesions. While the postoperative serum sFas and sFasL in BC1, and BC2 were significantly decreased than the preoperative levels but still significantly higher than the control level. Furthermore, this study showed in BC group the preoperative serum sFas and sFasL were significantly positively correlated with the nodal involvement. Also, serum sFasL. in BC group showed significant positive correlation with the lesion diameter. But, serum sFas showed non significant correlation with lesion diameter. As regard benign breast lesions, there was non significant increase in both serum sFas and sFasL compared to control group. We could conclude that the biochemical changes in serum sFas and sFasL may be considered useful tool as an apoptogenic marker in breast cancer